Retinal stem cell therapy - jCyte

Drug Profile

Retinal stem cell therapy - jCyte

Alternative Names: hRPC - jCyte; Human retinal progenitor cell therapy - jCyte; Human retinal progenitor cells - jCyte; jCell

Latest Information Update: 10 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator jCyte
  • Class Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinitis pigmentosa

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Retinitis pigmentosa in USA (Intravitreous) (NCT03073733)
  • 01 Jun 2015 Phase-I/II clinical trials in Retinitis pigmentosa in USA (Intravitreous) (NCT02320812)
  • 06 Jan 2015 jCyte plans a phase I/II trial for Retinitis pigmentosa in USA (NCT02320812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top